Poster Session 9 – Wednesday, December 9, 2020: 8:00 AM CT
  Psychosocial, Quality of Life and Educational Aspects
PS9-01 Consumer and patient reactions to trials of chemotherapy reductions reveal an urgent need to name and explain the concept
Smith ML, Railey E, White CB, Hill J, Andrews CJ, Rocque GB. Research Advocacy Network, Plano, TX; CBWhite, Evanston, IL; Soar Strategies, Evanston, IL; University of Alabama at Birmingham, Birmingham, AL.
PS9-02 Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens
Moy B, Oliveira M, Saura C, Gradishar W, Kim S-B, Brufsky A, Hurvitz S, Ryvo L, Fagnani D, Chan N, Kalmadi SR, Silverman P, Delaloge S, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R. Massachusetts General Hospital Cancer Center, Boston, MA; Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; University of Ulsan College of Medicine, Seoul, Republic of Korea; Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Assuta Ashdod Medical Center, Ashdod, Israel; ASST di Vimercate, Vimercate, Italy; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ironwood Cancer and Research Center, Chandler, AZ; University Hospitals Cleveland Medical Center, Cleveland, OH; Intitute Gustave Roussy, Villejuif, France; Puma Biotechnology Inc., Los Angeles, CA; Puma Biotechnology Inc., University of California San Francisco, South San Francisco, CA; Washington University School of Medicine, St. Louis, MO.
PS9-03 Reported concerns and acceptance of information or referrals among survivors with breast cancer seen for survivorship care planning visits: Results from the University of Wisconsin Carbone Cancer Center (UWCCC) Survivorship Program
Cha L, Tevaarwerk AJ, Smith EM, Chandereng T, Huenerberg KJ, Seaborne LA, Sesto ME. University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin, Department of Medicine and Carbone Cancer Center, Madison, WI; UW Health, Madison, WI; University of Wisconsin-Madison, Madison, WI.
PS9-04 The optimal living and survivorship program: Piloting a novel cancer survivorship care model
Corcoran S, Russell J, Clayton J, Smith A, Keenan K, Robson M, Iyengar N. Memorial Sloan Kettering Cancer Center, New York, NY.
PS9-05 Concordance between patient-reported and physician-documented comorbidities among stage 4 breast cancer patients
Umashankar S, Melisko ME, Matthys M, Van't Veer L, Basu A. University of California, San Francisco, San Francisco, CA.
PS9-06 Adherence to and patient satisfaction with the combination therapy of exemestane and everolimus in postmenopausal women with HR+ HER2- advanced breast cancer: Results from the IPSOC-mamma study
Foulon V, Visser C, De Coster S, Kinnaer L-M, Reynders E, Deblander A, Berteloot P, Punie K, Wildiers H, Cocquyt V, Denys H, Awada A, Strobbe E, Gombos A, Spoormans I, Elzo-Kraemer X, Vulsteke C, Borms M, Debruyne P, Wynendaele W, Neven P. Klinische Farmacologie en Farmacotherapie, Leuven, Belgium; UZ Leuven, Leuven, Belgium; UZ Gent, Gent, Belgium; Institut Bordet, Brussel, Belgium; Novartis, Vilvoorde, Belgium; AZ Damiaan, Oostende, Belgium; AZ Maria Middelares, Gent, Belgium; AZ Groeninge, Kortrijk, Belgium; AZ Imelda, Bonheiden, Belgium.
PS9-07 Metastatic breast cancer patients’ preferences and expectations for oral chemotherapy
Jaisle A, Fortune EE, Jacobs J, Saxton C, Ackourey J, Zaleta AK. Cancer Support Community, Philadelphia, PA; Harvard Medical School, Boston, MA; Cancer Support Community, Washington, DC.
PS9-08 The psychosocial impact of caregiving on partners of young women with breast cancer in treatment
Gray TF, Borstelmann N, Rosenberg S, Gelber S, Meyer ME, Ruddy KJ, Schapira L, Come S, Borges V, Cadet T, Maramaldi P, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Stanford University School of Medicine, Palo Alto, CA; Beth Israel Deaconess Medical Center, Boston, MA; University of Colorado, Aurora, CO; Simmons College School of Social Work, Boston, MA.
PS9-09 Web-based intervention to improve knowledge, intent to screen and uptake of breast cancer screening among long-term, high-risk Hodgkin lymphoma survivors who received chest radiation
Sagaram S, Jewett P, Vogel RI, Turcotte L, Sadak K, Beckwith H, Potter D, Yee D, Lee HY, Blaes A. University of Minnesota, Minneapolis, MN; University of Alabama, Tuscaloosa, AL.
PS9-10 Can composite risk model help clinicians make adjuvant ovary function suppression dicision for breast cancer patients
Liang Y, Chen X, Gao W, Zhu S, Hong J, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Shen K. Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
PS9-11 Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer
Cardoso F, Cortes J, Gradishar W, Im S-A, Pegram MD, Rugo HS, Wright GS, De Laurentiis M, Levy C, Ferrero J-M, Mansi J, Oyola R, Ricci F, Jakobsen EH, Uziely B, Egle D, Giagounidis A, Williams K, Hong S, Rock E, Curigliano G. Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal; IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona; Vall d' Hebron Institute of Oncology, Barcelona, Spain; Northwestern University, Division of Hematology/Oncology, Chicago, IL; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Stanford Women's Cancer Center, Breast Cancer Oncology Program, Palo Alto, CA; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Florida Cancer Specialists & Research Institute, New Port Richey, FL; Istituto Nazionale Tumori IRCCS "Fondazione Pascale," Department of Breast and Thoracic Oncology, Naples, Italy; Centre Francois Baclesse, Institut Normand du Sein, Caen, France; Centre Antoine Lacassagne, Department of Medical Oncology, Nice, France; Cancer Centre London, Guys and St. Thomas Hospital, London, United Kingdom; Northwest Georgia Oncology Centers, Marietta Cancer Center, Marietta, GA;; Department of Medical Oncology, Institut Curie, Paris, France; Vejle Hospital, Department of Oncology, Vejle, Denmark; Hadassah Medical Organisation, Hadassah Medical Center, Jerusalem, Israel; Department of Gynecology and Obstetrics, Universitatsklinik Innsbruck, Innsbruck, Austria; Clinic for Hematology, Oncology, and Palliative Care, Marien Hospital, Dusseldorf, Germany; MacroGenics, Inc., Rockville, MD; University of Milano, European Institute of Oncology, IRCSS, Division of Early Drug Development, Milan, Italy.
PS9-12 Vitamin and supplement use and documentation in a breast cancer survivorship clinic
Moore A, Silver J, Goldenberg A. Weill Cornell Medicine, New York, NY.
PS9-13 Decision making process and contralateral prophylactic mastectomy
Alameddine HF, Singareeka A, Andersen C, Selber J, Brewster A, Barcenas CH, Caudle A, Arun B, Ibrahim N. Kindred Hospital, Sugar Land, TX; MD Anderson Cancer Center, Houston, TX.
PS9-14 Feasibility of monitoring symptoms during endocrine therapy with patient reported outcomes collected via smart phone app
Smith KL, Wang C, Lim D, Montanari A, Nunes R, Wilkinson1 MJ, Sheng JY, Couzi R, Fetting J, Riley C, Wolff AC, Santa-Maria CA, Papathakis K, Collins-Chase L, Hilton C, Snyder C, Thorner E, Ikejiani DZ, Steimer M, Stearns V. Johns Hopkins, Baltimore, MD; Sibley Memorial Hospital, Washington, DC; Allegheny Health Network, Pittsburgh, PA.
PS9-15 Utilizing education to strengthen oncologist' understanding of immunotherapy in triple negative breast cancer
Parikh K, Warren C, Kugel P, Carothers A, Kadkhoda H, Emens L. Medscape Oncology, Houston, TX; Medscape Oncology, New York, NY; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA.
PS9-16 Long-term personal, social and financial impact of advanced breast cancer: Results from the invisible woman 2.0, a pan-European patient and carer survey
Decise DONA, Harmer VICT, Musaian MARI, Aubel DAWN, Cardoso FATI. Novartis Oncology Region Europe, Origgio, Italy; Imperial College Healthcare NHS Trust, London, United Kingdom; Novartis Global Oncology, East Hanover, NJ; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
PS9-17 Nurse navigation in the ambulatory oncology clinic: Patient-centered findings from a survey of 50 breast cancer patients
Wang T, Huilgol Y, James J, Belkora J, Black J, D'Andrea C, Esserman L. UCSF Breast Care Center, San Francisco, CA; UCSF School of Medicine, San Francisco, CA; UCSF School of Nursing, San Francisco, CA; Night Cancer Institute at Oregon Health and Sciences University, Portland, OR.
PS9-18 Relative risk of various endocrinopathies associated with the use of chemoimmunotherapy for triple-negative breast cancer: A systematic review and meta-analysis
Jahan N, Wongsaengsak S, Singal S, Rehman S, Hardwicke F, Jones C. Texas Tech University Health Sciences Center, Lubbock, TX; East Tennessee State University, Johnson City, TN.
PS9-19 Health-related quality of life (HRQOL) outcomes in arandomized controlled trial of yoga in breast and gynecological cancer survivors with chemotherapy-induced peripheral neuropathy
Zhi WI, Baser R, Zhi L, Piulson L, Li Q; Bao T. MSKCC, Breast Medicine, New York, NY; MSKCC, Dept of Epidemiology-Biostatistics, New York, NY; Ward Melville High School, East Setauket, NY; MSKCC, Ingetive Medicine, New York, NY; MSKCC, Integrative Medicine, New York, NY; MSKCC, Integrative Medicine, New York, NY.
PS9-20 Prospective observational study of chemotherapy-induced alopecia after sequential FEC+taxane and the effects of age in breast cancer patients
Fujii T, Ichiba K, Honda C, Nakazawa Y, Ogino M, Kurozum S, Obayashi S, Yajima R. Gunma University, Maebashi, Japan.
PS9-21 Patient reported outcomes of newly diagnosed women with breast cancer enrolled in a digital health coaching program
Brassil KJ, Fellman B, Wisse B, Urbauer D, Shelton V, Harty C, Rasulnia M. Pack Health, Birmingham, AL; The University of Texas MD Anderson Cancer Center, Houston, TX.
PS9-22 Supportive care needs and patient experience of women with metastatic breast cancer in a safety-net system
Buchanan A, El-Mubasher O, Sarfo A, Badr H. Baylor College of Medicine, Houston, TX.
PS9-23 Second-generation HR-pQCT analysis of bone mineral density and microstructure in women with breast cancer who underwent adjuvant endocrine therapy
Kuba S, Watanabe K, Matsumoto M, Chiba K, Yamanouchi K, Fukushima A, Morita M, Otsubo R, Yano H, Kanetaka K, Osaki M, Nagayasu T, Eguchi S. Nagasaki University, Nagasaki, Japan.
PS9-24 Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer
Gupta T, Purington N, Liu M, Han S, Sledge G, Schapira L, Kurian A. Stanford, Palo Alto, CA.
PS9-25 Receipt of preventive care and health promotion in a cohort of early stage breast cancer survivors
Schumacher JR, Haine JE, Tevaarwerk AJ, Kwekkeboom KL, Stankowski-Drengler TJ, Breuer CR, Tucholka JL,Maxcy C, Smith MA, Neuman HB. University of Wisconsin, Madison, WI.
PS9-26 Pelvic floor disorders and quality of life among breast cancer survivors
Pennycuff JF, Yang F, Lobo T, Jackman C, McGuire C, Chitalia A, Graves K. Medstar/Georgetown School of Medicine, Washington, DC; Georgetown University Lombardi Comprehensive Care Center, Washington, DC; Georgetown University School of Medicine, Washington, DC.
PS9-27 Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system
Pimentel FF, Buzatto IPC, Rodrigues TCGF, Borba JMC, Peruchi KPI, de Andrade JM, Tiezzi DG. Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
PS9-28 Patient knowledge, attitudes and perceptions regarding breast cancer biomarkers, testing, and quality of life
Rugo HS, Shanahan K, Attias E, Portman M, Gencarelli J. University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; METAvivor, South Lake Tahoe, CA; Sermonix Pharmaceuticals, Columbus, OH.
PS9-29 Factors influencing fatigue in breast cancer patients undergoing breast irradiation
Perry E, Mulay S, Kamath J, Dowsett R, Wu R, Wang X, Greenwood M, Neuwirth J, Grady J, Liang B, Tannenbaum S. UConn Health, Farmington, CT.
PS9-30 The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy
Mansour R, Al-Rasheed U, Al-Ibraheem A, Jaradeh SA, Abdel-Razeq R, Bater R, Mashahdani N, Tbayshat S, Abdel-Razeq H. King Hussein Cancer Center, Amman, Jordan.
PS9-31 Developing an outreach model to healthcare providers treating newly diagnosed metastatic breast cancer patients
Ormerod CL, Washburn S, Swiger KD, O'Neill C. Living Beyond Breast Cancer, Bala Cynwyd, PA; Global Consultant, Patient Relations/Advocacy, Greensboro, NC.
PS9-32 Physical activity platform to improve bone health in cancer survivors
Skinner C. Thrivors Inc, Saint Paul, MN.
PS9-33 Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US
Brodtkorb T-H, McDade C, Lalla D, Holmes FA. RTI-HS, Ljungskile, Sweden; RTI Health Solutions, Research Triangle Park, NC; Puma Biotechnology, San Francisco, CA; Institution: Texas Oncology, US Oncology, Research, Houston, TX.
PS9-34 Initial experience using the SOZO bio-impedance device over a 2 year surveillance period for identifying subclinical breast cancer related lymphedema (BCRL) in patients attending a multidisciplinary breast clinic
Pfeiffer D, Lord M, Lamb C, Damrill K, Stewart K, Rock DT. LeeHealth Regional Cancer Center, Fort Myers, FL.
PS9-35 Volumetric assessment of lymphedema with 3D sensor
Maciel-Miranda A, Otero-Hernández MI, Martínez-Silva D, Escrivá-Machado JF. ANKER Oncología Global, Guadalajara, Mexico; Centro Oncológico Internacional, Guadalajara, Mexico; Clínica Método Proa-Medicina de Rehabilitación, Guadalajara, Mexico; Clínica Dr. Escrivá, Tepic, Mexico.
PS9-36 Exercise therapy to reduce breast cancer fatigue: results from the EXPECT study
Invernizzi M, de Sire A, Sajjadi E, Venetis K, Gennari A, Fusco N. University of Eastern Piedmont, Novara, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
PS9-37 Hereditary breast and ovarian cancer syndrome (HBOC) diagnosis impacts more the life quality of women than men: A case-control report
Barbosa Oliveira FF, de Barros Silva PG, Silva-Fernandes IJ, Picanço-Albuquerque CG, dos Santos Luciano MC, Barbosa Bezerra MJ, Sant´anna RO, Bitencourt FS, Alves Lima MV. Haroldo Juaçaba Hospital, Fortaleza, Brazil.
PS9-38 Improving adherence to hormone therapy among breast cancer patients through a mobile app and patient navigation: App development and testing
Chalela P, Munoz E, Despres C, Sukumaran P, Tiemann I, Paz V, Gutierrez B, Inupakutika D, Kaghyan S, Akopian D. UT Health San Antonio - Institute for Health Promotion Research, San Antonio, TX; The University of Texas at San Antonio, San Antonio, TX.
PS9-39 The day after - a comprehensive rehabilitation program for breast cancer survivors
Rosengarten OS, Constantinin N, Bertisch M. Shaare Zedek Medical Center, Jerusalem, Israel.
PS9-40 Multiple activities improve oncologists' knowledge and competence with CDK4/6 inhibitors in HR+ breast cancer over time
Parikh K, Dorkhom N, Chen P, Ragoonath Cameron D, Tanzola M, Peters P, Tolaney S. Medscape Oncology, Houston, TX; Medscape Oncology, New York, NY; Dana-Farber Cancer Institute, Boston, MA.
PS9-41 Tailored education prescribed throughout the breast cancer journey via a mobile application
Alford SH, Kumar T, Mahatma S. Cancer Insights, Chappaqua, NY.
PS9-42 Understanding genomic testing in real-world populations at Outcomes4Me (GENOME)
Stroiney AG, Rahma OE, Said MR. Outcomes4Me Inc., Cambridge, MA.
PS9-43 Impact of educational workshops on patient-provider communication among Spanish-speaking metastatic breast cancer survivors and their caregivers: Results from the Frankly Speaking about Cancer: Cáncer de seno métastatico evidence-based educational workshops
Saxton C, Gonzalo MB, Ruwala R, Fearnley K, Jaisle A. Cancer Support Community, Washington, DC; Cancer Support Community, Research and Training Institute, Philadelphia, PA.
PS9-44 Breaking the silent struggles: Development of a cancer caregiver support program
Koerber JM, Solti M. Compass Oncology, Vancouver, WA.
PS9-45 Factors causing delayed resolution of breast lymphoedema
Chigurupati P, Gowd M, Elwell R, Hawazie A, Kabeer KK, Marla S, Jafferbhoy S, Soumian S, Narayanan S. Royal Stoke University Hospital, North midlands, Stoke on Trent, United Kingdom.
PS9-46 Pre-diagnosis major life stressors and breast cancer outcomes
Pai T, Vallow L, Seneviratne D, Mussallem D, Cornell L. Mayo Clinic Florida, Jacksonville, FL.
PS9-47 A scoping review characterizing “choosing wisely” recommendations for breast cancer management
Shah H, Surujballi J, Awan AA, Hutton B, Angel Arnaout A, Shorr R, Vandermeer L, Alzahrani MJ, Clemons M. University of Ottawa, Ottawa, ON, Canada; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The University of Ottawa School of Epidemiology and Public Health, and Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Surgery, The Ottawa Hospital, Ottawa, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre, The University of Ottawa School of Epidemiology and Public Health, and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
PS9-48 Depression, sexual dysfunction and quality of life among breast cancer patients with ovarian function suppression: A cross sectional study between ovarian ablation verse GnRH agonists
Xu J, Sun T. Liaoning Cancer Hospital & Institute, Shenyang, China
PS9-49 Comparison of the quality of life (QOL) of patients with an arm vein port (TIVAD) versus a peripherally inserted central catheter (PICC)
Ahmed S, Burbridge B, Dwernychuk L, Le H, Asif T, Lim H. Saskatchewan Cancer Agency, Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Saskatchewan Cancer Agency. Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Clinical Research Support Unit. College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
PS9-50 A multicenter, prospective, observational study to determine the incidence of febrile neutropenia (FN), persistence and G-CSF utilization among cancer patients at high risk for FN receiving pegfilgrastim by an on-body injector (OBI) versus other FN prophylaxis strategies: An interim analysis
Mahtani1 RL, Crawford J, Rifkin R, Dale D, Brookhart A, Gawade PL, Lewis S, Lawrence T, Belani R, Lyman GH. Division of Hematology/Oncology Sylvester Comprehensive Cancer Center, University of Miami Health System, Deerfield Beach, FL; Duke University School of Medicine, Durham, NC; Research Rocky Mountain Cancer Centers – Midtown, Denver, CO; Department of Medicine, University of Washington, Seattle, WA; Duke University, Durham, NC; Amgen Inc., Thousand Oaks, CA; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.
PS9-51 Secondary outcomes in a randomized controlled trial of acupuncture versus sham acupuncture and usual care in solid tumor survivors with chemotherapy-induced peripheral neuropathy
Bao T, Baser R, Lin C, Li Q, Piulson L, Zhi I. Memorial Sloan Kettering Cancer Center, New York, NY.
PS9-52 A randomized phase II trial of interventions with frozen groves and compression stockings to prevent nab-paclitaxel induced chemotherapy-induced peripheral neuropathy (SPOT trial)
Kashiwaba M, Nakayama T, Sangai T, Morimoto T, Yasojima H, Yamamoto Y, Ohno S, Masuda N. Adachi Nyusen Clinic, Kyoto, Japan; Dpt of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan; Dpt of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan; Dpt of Breast Surgery, Yao Munucipal Hospital, Yao, Japan; Dpt of Breast Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan; Dpt of Breast and Endocrine Surgery, Kumamoto University, Kumamoto, Japan; Breast Center, Cancer Institute Hospital of JFCR, Tokyo, Japan.
PS9-53 Withdrawn
PS9-54 Healthcare costs for metastatic breast cancer patients treated with human epidermal growth factor receptor 2 targeted agents
Mahtani R, Lalla D, Oestreicher N, Ogbonnaya A, Saundankar V, Willey J, Coutinho A, McCann K. Sylvester Cancer Center, University of Miami, Deerfield Beach, FL; Puma Biotechnology Inc, South San Francisco, CA; Puma Biotechnology, Inc; University of California, San Francisco, Department of Clinical Pharmacy, San Francisco, CA; Xcenda LLC, Palm Harbor, FL; University of California, Los Angeles, Los Angeles, CA.
PS9-55 Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis
Sripada K, Manjrekar S, Klein-Panneton K, Coombes M, Ferrario C. Roche Canada, Mississauga, ON, Canada; Jewish General Hospital, Montreal, QC, Canada.
PS9-56 High compliance with choosing wisely breast procedures at a safety net hospital
Tang A, Mooney C, Ugarte S, Knopf K, Khoury A. University of California San Francisco, East Bay, Oakland, CA; Alameda Health System, Oakland, CA.
PS9-57 Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A); Preliminary study findings
Iwatani T, Hara F, Shien T, Takahashi M, Masuda N, Yasojima H, Sagara Y, Mizutani T, Sasaki K, Nakamura K, Fukuda H, Shiroiwa T, Iwata H. National Cancer Center Hospital East, Kashiwa, Japan; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sagara Hospital, Kagoshima, Japan; Kyorin University Faculty of Medicine, Tokyo, Japan; Japan Clinical Oncology Group (JCOG) Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Wako, Japan; Aichi Cancer Center, Nagoya, Japan.
PS9-58 Factors associated with sexual problems during adjuvant endocrine therapy
Verma N, Blackford AL, Lim D, Thorner E, Lehman J, Snyder C, Snyder CA, Stearns V, and Smith KL. Johns Hopkins School of Medicine, Baltimore, MD; Sibley Memorial Hospital, Baltimore, MD.
PS9-59 Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer
Schwartzberg LS, Bhat G, Restrepo A, Hlalah O, Mehmi I, Moon YW, Baek S, Chawla S, Lebel F, Cobb PW. West Cancer Center, Germantown, TN; Spectrum Pharmaceuticals, Inc, Irvine, CA; Texas Oncology PA, McAllen, TX; Bond Clinic PA, Winter Haven, FL; The Angeles Clinic and Research Institute, Los Angeles, CA; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; Hanmi Pharmaceuticals, Seoul, Republic of Korea; Spectrum Pharmaceuticals, Inc., Irvine, CA; Frontier Cancer Center, Billings, MT.
PS9-60 Insomnia is the most disturbing symptom during breast cancer treatment: Results from a Brazilian cohort using a patient-reported outcomes: PRO tool - Tummi App
Menezes Morelle A, Castilho Venero F, DalPonte Ferreira R, FabricioPereirada Silva R, Tofani Sant'Anna P. Hospital Moinhos de Vento, Porto Alegre, Brazil.
PS9-61 Incidence of intravenous (IV) hydration post anthracycline-cyclophosphamide (AC) chemotherapy in breast cancer patients
Navari RM, Mosier MC. University of Alabama at Birmingham School of Medicine; Dr. Navari is now with Cancer Care Program, Central and South America, World Health Organization, Birmingham, AL; EMB Statistical Solutions, LLC, Overland Park, KS.
PS9-62 Biopsychosocial approach in the rehabilitation of patients with early breast cancer
Kluge V, Semiglazova T, Krivorotko P, Melnikova E, Semiglazov V, Kondrateva K, Nazarova S, Tynkasova M, Adhamov B, Pesotsky R, Zernov K, Chulkova V, Kasparov B, Kovlen D, Semiglazov V, Belyaev A. FSBI Petrov Scientific and Research Institute of Oncology of the Ministry of Health of Russia, Saint-Peterburg, Russian Federation; State Budgetary Educational Institution of Higher Professional Education Pavlov Saint-Petersburg State Medical University of the Ministry of Health of Russia, Saint-Peterburg, Russian Federation; S. M. Kirov Military Medical Academy, Saint-Peterburg, Russian Federation.
PS9-63 Real world data on the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer
Flood WA, Avery T, Kozlovsky V, Margolis N, Reddy S. NantHealth, Philadelphia, PA; NantHealth, El Segundo, CA.
PS9-64 Impact of online education regarding novel HER2 therapies on translating evidence to practice
Parikh K, Dorkhom N, Chen P, Ragoonath Cameron D, Caraico R, Hanley K; Modi S. Medscape Oncology, Houston, TX; Medscape Oncology, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY.
PS9-65 Effect of virtual education on the knowledge, competence, and performance of oncology pharmacists attending a national symposium
Carranza V, Fowler JB, Gitzinger SH, Taylor BC. Creative Educational Concepts, Lexington, KY.
PS9-66 Pilot study for the use of a booklet for breast cancer patients who receive radiation therapy at National Cancer Institute of Mexico
Rivera-Sánchez D, Gutiérrez-Zacarías LM, Torres-Domínguez JA, Guerra-Vázquez P, Bargalló-Rocha JE. Instituto Nacional de Cancerología, Mexico City, Mexico.
PS9-67 Information needs, media use, and utilization of an online resource to support how young women with metastatic breast cancer evaluate breast cancer media reports
Pugh Yi RH, Welcsch P, Dearfield C, Owens K, Friedman S. Akeso Consulting, Vienna, VA; FORCE, Tampa, FL.
PS9-68 Budget impact of Ontruzant for the treatment of breast cancer and gastric cancer in the United States
Huang M, Singhal P, Shinde R, Wilkes SK, Nagda N, Yi Y, Lucherini S. Merck & Co., Inc., North Wales, PA; Adelphi Values PROVE, Bollington, United Kingdom.
PS9-69 Findings from the BonE heAlth eduCatiOn needs assessment (BEACON) study: A survey of bone metastatic breast cancer patients at risk for skeletal-related events
Flora DR, Carlson KB, Lowe K, Cadieux B, Boike G, Bachmann B, Fuehrer DC. GRYT Health Inc., Rochester, NY; Amgen Inc., Thousand Oaks, CA; Karmanos Cancer Institute, Bay City, MI.
PS9-70 Identifying barriers and facilitators to scalp cooling use through a national survey of the awareness, practice patterns, and attitudes of oncologists toward scalp cooling
Novice M, Novice T, Jeruss J, Johnson K, Burness M. University of Michigan, Ann Arbor, MI; St Joseph Mercy Hospital, Ann Arbor, MI.
PS9-71 The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer
Guler Ilhan R, Ilhan Y, Sezgin Goksu S, Tatli AM, Coskun HS. Akdeniz University Faculty of Medicine, Antalya, Turkey.
PS9-72 Fertility preservation in breast cancer patients
Baulies S, Izquierdo M, Devesa M, Rodriguez I, Tresserra F, Fàbregas R. Hospital Universitari Quirón Dexeus, Barcelona, Spain.